FI3878444T3 - (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena - Google Patents

(n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena Download PDF

Info

Publication number
FI3878444T3
FI3878444T3 FIEP20216249.1T FI20216249T FI3878444T3 FI 3878444 T3 FI3878444 T3 FI 3878444T3 FI 20216249 T FI20216249 T FI 20216249T FI 3878444 T3 FI3878444 T3 FI 3878444T3
Authority
FI
Finland
Prior art keywords
naphthamide
benzylphenyl
oxoethyl
amino
therapeutic agent
Prior art date
Application number
FIEP20216249.1T
Other languages
English (en)
Finnish (fi)
Inventor
Robert J Hickey
Linda H Malkas
Original Assignee
Rll Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rll Llc filed Critical Rll Llc
Application granted granted Critical
Publication of FI3878444T3 publication Critical patent/FI3878444T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FIEP20216249.1T 2015-04-10 2016-04-08 (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena FI3878444T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/684,259 US10420840B2 (en) 2015-04-10 2015-04-10 Anticancer therapeutic agents

Publications (1)

Publication Number Publication Date
FI3878444T3 true FI3878444T3 (fi) 2024-11-19

Family

ID=57072079

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20216249.1T FI3878444T3 (fi) 2015-04-10 2016-04-08 (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena

Country Status (12)

Country Link
US (1) US10420840B2 (enExample)
EP (2) EP3280261B1 (enExample)
JP (1) JP6748704B2 (enExample)
CN (1) CN107404876B (enExample)
AU (1) AU2016245886B2 (enExample)
BR (1) BR122023024844A2 (enExample)
CA (1) CA2978965C (enExample)
ES (1) ES2991018T3 (enExample)
FI (1) FI3878444T3 (enExample)
PL (2) PL3280261T3 (enExample)
PT (1) PT3878444T (enExample)
WO (1) WO2016164707A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119013247A (zh) * 2022-03-07 2024-11-22 希望之城 Pcna抑制剂及其用途
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
EP1874823B1 (en) 2005-04-27 2016-01-13 Indiana University Research and Technology Corporation Cancer specific pcna isoform binding antibodies and uses thereof
CA2612695A1 (en) * 2005-06-27 2007-01-04 Derek J. Hoelz Cspcna isoform modifications and uses thereof
CN101384618A (zh) * 2006-02-17 2009-03-11 印第安纳大学研究及科技有限公司 癌中capcna蛋白-蛋白相互作用的肽基抑制
US20090123487A1 (en) 2007-09-19 2009-05-14 Katia Rothhaar Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CA2732737C (en) * 2008-07-24 2019-03-05 Indiana University Research And Technology Corporation Cancer peptide therapeutics
WO2011044374A1 (en) * 2009-10-07 2011-04-14 Indiana University Research And Technology Corporation Capcna peptide therapeutics for cancer
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
US10550070B2 (en) * 2015-09-17 2020-02-04 City Of Hope PCNA inhibitors

Also Published As

Publication number Publication date
AU2016245886A1 (en) 2017-10-12
EP3280261A1 (en) 2018-02-14
JP2018510917A (ja) 2018-04-19
EP3280261A4 (en) 2018-12-12
AU2016245886B2 (en) 2020-04-30
CN107404876A (zh) 2017-11-28
US20160296482A1 (en) 2016-10-13
PT3878444T (pt) 2024-11-08
US10420840B2 (en) 2019-09-24
PL3878444T3 (pl) 2025-01-07
CA2978965A1 (en) 2016-10-13
EP3878444A1 (en) 2021-09-15
BR112017019983A2 (pt) 2018-06-19
PL3280261T3 (pl) 2021-09-06
CA2978965C (en) 2023-11-14
EP3878444B1 (en) 2024-10-09
WO2016164707A1 (en) 2016-10-13
EP3280261B1 (en) 2020-12-23
BR122023024844A2 (pt) 2024-01-23
ES2991018T3 (es) 2024-12-02
CN107404876B (zh) 2023-04-14
JP6748704B2 (ja) 2020-09-02

Similar Documents

Publication Publication Date Title
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
IL250239A0 (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
MA42032A (fr) Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
HUE039809T2 (hu) Vegyület karbamid-tartalmú mûtrágyák kezelésére
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
CR20170315A (es) Inhibridores bace 1 selectivos
LT3436074T (lt) Tiazolido junginiai, skirti virusinių infekcijų gydymui
HUE045226T2 (hu) Herbicid hatású N-(1,3,4-oxadiazol-2-il)arilkarboxamid-származékok
HUE059584T2 (hu) Gyógyszerészeti készítmény vérszegénység kezelésére
CO2018001383A2 (es) Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp”
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
EP3856174A4 (en) HDAC1, 2 INHIBITORS
DK3728220T3 (da) Farmaceutiske forbindelser
FI3878444T3 (fi) (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena
EA201891688A1 (ru) Адамантановое производное и его применение
EA201792109A1 (ru) Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера
EA201690908A1 (ru) Пиразолопиримидиновые соединения
IT201700123080A1 (it) Macchina per l'assemblaggio di dispositivi medicali.
KR101827245B9 (ko) 알라린을 주성분으로 하는 요독증 치료제
MX379649B (es) Derivados de azetidina para formacion de imágenes de tau.
DK3164385T3 (da) Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers
RU2016108801A (ru) Пептид, обладающий лечебным действием против болезни Альцгеймера
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid